{"url_path":"/sec/nktx/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1787400/0001787400-26-000013-index.html","accession_number":"0001787400-26-000013","cik":"0001787400","ticker":"NKTX","issuer_name":"Nkarta, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787400/0001787400-26-000013-index.html","primary_entity_key":"0001787400","primary_entity_name":"Nkarta, Inc."},"word_count":90,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nDuring the quarter ended March 31, 2026, the following officers adopted a \"Rule 10b5-1 trading arrangement\" (as such terms are defined in Item 408(a) of Regulation S-K) as noted in the table below.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nTrading Arrangement\n\n \n\n \n\n \n\n \n\n \n\nName and Title\n\n \n\nAction\n\n \n\nDate\n\n \n\nRule 10b5-1\n\n \n\nNon-Rule 10b5-1\n\n \n\nTotal Shares to be Sold\n\n \n\n \n\nExpiration Date\n\nPaul Hastings\nChief Executive Officer\n\n \n\nAdoption\n\n \n\n1/22/2026\n\n \n\nX\n\n \n\n \n\n \n\n \n\n300,000\n\n \n\n \n\n3/19/2027\n\nNadir Mahmood\nPresident\n\n \n\nAdoption\n\n \n\n2/18/2026\n\n \n\nX\n\n \n\n \n\n \n\n \n\n205,416\n\n \n\n \n\n5/28/2027\n\nShawn Rose\nChief Medical Officer and Head of Research & Development\n\n \n\nAdoption\n\n \n\n2/12/2026\n\n \n\nX\n\n \n\n \n\n \n\n \n\n177,250\n\n \n\n \n\n5/28/2027\n\n79"}